secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001651308-25-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B
--------------------------------------------------------------------------------

- Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).
- BRUKINSA global revenue Q4 $828M (+100%); full year $2.6B (+105%).
- Full year 2025 revenue guidance $4.9-$5.3B; anticipate positive GAAP operating income in 2025.
- GAAP operating loss narrowed to $79M in Q4 from $384M; achieved positive non-GAAP operating income of $79M.
- Advanced 6 NMEs in Q4 and 13 in full year; plan to change name to BeOne Medicines Ltd., ticker ONC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/0001651308-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/bgne-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer